| Species |
Human |
| Protein Construction |
TGF-β2 (Ala303-Ser414)
Accession # P61812 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
ED50 < 0.2 ng/ml, measured in a cell proliferation assay using mouse HT-2 cells. |
| Expression System |
Human Cells |
| Apparent Molecular Weight |
~12.7 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 4 mM HCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Transforming growth factor beta-2 (TGF-β2) is a secreted protein which belongs to the TGF-beta family. It is known as a cytokine that performs many cellular functions and has a vital role during embryonic development. The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive. It is an extracellular glycosylated protein. It is known to suppress the effects of interleukin dependent T-cell tumors. Defects in TGFB2 may be a cause of non-syndromic aortic disease (NSAD). |
| Synonyms |
Transforming growth factor beta-2; TGFB2; Polyergin; G-TSF; Glioblastoma-derived T-cell suppressor factor; Cetermin; BSC-1 cell growth inhibitor; TGF-beta-2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
